BioStem Technologies (OTCMKTS:BSEM) Upgraded at Zacks Research

Zacks Research upgraded shares of BioStem Technologies (OTCMKTS:BSEM) to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

BioStem Technologies Trading Down 0.2%

BioStem Technologies stock opened at $5.07 on Wednesday. BioStem Technologies has a 52 week low of $3.09 and a 52 week high of $15.74. The stock has a market cap of $85.38 million, a P/E ratio of 5.96 and a beta of -0.33. The stock has a 50 day moving average of $5.65 and a 200-day moving average of $4.97.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.